Gedeon Richter (RICHTER) Investor presentation summary

Company overview and strategic vision

• Over 125 years of history, with ~11,500 employees and 8 manufacturing sites globally.

• Four business units: Women's Healthcare (WHC), Neuropsychiatry/CNS, Biotechnology (BIO), and General Medicines (GM).

• Vision for 2035 focuses on global recognition, pharma-only innovation, and affordable medicines, with a special focus on women and mental health.

• Aims to double non-royalty business size and add royalties by the 2030s.

Business unit performance and growth drivers

• WHC is set to become the largest EBIT contributor by 2035, targeting double revenue and R&D investment.

• CNS driven by Cariprazine (Vraylar®), a top-selling drug in the US, with global expansion and new indications.

• Biotech segment targets double-digit growth, break-even by 2027, and multiple biosimilar launches.

• GenMed aims to double revenue by 2035, focusing on cardiovascular, CNS, blood therapies, and diabetes/obesity.

Financial highlights and outlook

• 2025 sales revenue reached EUR 2.3bn, with a market cap of ~EUR 6.6bn.

• Q1 2026 revenues grew 5.9% at constant exchange rates (CER), with Clean EBIT up 15% CER.

• WHC, Vraylar®, and BIO segments outperformed, while GenMed lagged due to market conditions.

• Clean EBIT margin expected to exceed 20% by 2030-31, driven by operational excellence and portfolio development.

• Capital allocation prioritizes R&D (30-35% of pre-R&D cash), with sustained dividends and flexibility for external innovation.